Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Essex Bio-Technology Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Essex Bio-Technology has a total shareholder equity of HK$2.0B and total debt of HK$306.5M, which brings its debt-to-equity ratio to 15.2%. Its total assets and total liabilities are HK$3.0B and HK$950.3M respectively. Essex Bio-Technology's EBIT is HK$321.4M making its interest coverage ratio -46.3. It has cash and short-term investments of HK$600.6M.
Anahtar bilgiler
15.2%
Borç/özkaynak oranı
HK$306.54m
Borç
| Faiz karşılama oranı | -46.3x |
| Nakit | HK$600.62m |
| Eşitlik | HK$2.02b |
| Toplam yükümlülükler | HK$950.33m |
| Toplam varlıklar | HK$2.97b |
Son finansal sağlık güncellemeleri
Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07
Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13
Recent updates
Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 1061's short term assets (HK$1.4B) exceed its short term liabilities (HK$824.2M).
Uzun Vadeli Yükümlülükler: 1061's short term assets (HK$1.4B) exceed its long term liabilities (HK$126.1M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 1061 has more cash than its total debt.
Borcun Azaltılması: 1061's debt to equity ratio has reduced from 22.1% to 15.2% over the past 5 years.
Borç Kapsamı: 1061's debt is well covered by operating cash flow (103%).
Faiz Kapsamı: 1061 earns more interest than it pays, so coverage of interest payments is not a concern.